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ABSTRACT  
Data are scarce about short-term right ventricular changes after intervention for 
pulmonary hypertension, in particular about Systemic Sclerosis associated 
pulmonary arterial hypertension (PAH).  
In this pilot study we have performed prospective short-term follow-up after 
intervention in 14 pulmonary hypertension patients using a novel echocardiography 
technique, 2D echocardiography knowledge based reconstruction (2DKBR) of the 
right ventricle. 12 patients had pulmonary arterial hypertension (PAH) and 2 had 
chronic thromboembolic pulmonary hypertension (CTEPH). The majority of the PAH 
patients had PAH associated with Systemic Sclerosis (n=8). Patients underwent 
either initiation of new targeted therapy (n=9) or escalation of targeted therapy for 
PAH (n=3) or pulmonary endarterectomy for CTEPH (n=2).  
After a mean follow up of 4.8 +/- 2.6 months 2DKBR detected significant 
improvements in the right ventricular end-diastolic volume index (107 +/- 22 vs 89 +/- 
20 ml/m²; p=0.015), end-systolic volume index (74 +/- 20 vs 55 +/- 17 ml/m²; 
p<0.001)) and ejection fraction (30 +/- 9 vs 39 +/- 9%; p=0.011). These changes 
were accompanied by significant changes in NT-proBNP (Median 209, IQ 364 vs 63, 
IQ 87) pmol/L; p=0.004) and 6MWT levels (241 +/- 124 vs. 375 +/-118 m; p=0.005). 
There were significant improvements of right ventricular volumes and ejection fraction 
shortly after intervention in a mixed pulmonary hypertension population which was 
dominated by systemic sclerosis associated PAH. 2D echocardiography using 
knowledge based reconstruction might be a useful alternative imaging modality to 
follow up patients with pulmonary hypertension. 
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Introduction 
Pulmonary hypertension (PH) leads to pressure overload of the right ventricle which 
causes hypertrophy and eventual failure of the right ventricle (RV). In terms of 
symptoms and prognosis in this patient group right ventricular function is the main 
determinant (1, 2).  
2D echocardiography, the most widely available cardiac imaging modality has 
significant limitations due to the unique crescent shape of the right ventricle(3). Both 
linear and RV area measurements can be challenging and can significantly 
underestimate true RV size(4). Also, parameters of systolic function assessed with 
2D-echocardiography showed only moderate correlation in several studies (5, 6).  
Cardiac magnetic resonance (CMR) imaging has evolved as the gold standard for 
imaging of the right ventricle(7) and studies have suggested that both changes in RV 
volume and ejection fraction (8-10) predict outcome in pulmonary hypertension. 
However CMR is costly, resource intensive and not widely available in low-income 
countries which makes it less suitable for serial follow, in particular short-term follow-
up. Also, CMR is contraindicated in many patients with implanted ferromagnetic 
devices. 
Commercially available 3D echocardiography has been compared to CMR, however 
this technique exhibits only moderate reproducibility of RV volumes and ejection 
fraction(11) and exhibits a negative bias in ejection fraction and RV volumes(12).  
We and others have recently compared 2D echocardiography knowledge-based 
reconstruction (2DKBR) of the right ventricle to CMR for volumetric quantification in 
pulmonary hypertension demonstrating good inter- and intraobserver reproducibility 
(5, 13). Feasibility of this method was also demonstrated in other studies (14-16).  
Data are scare about short-term right ventricular changes after intervention in 
pulmonary hypertension, in particular in pulmonary arterial hypertension associated 
with Systemic Sclerosis. In this paper we describe the use of short-term serial 
2DKBR to evaluate change in RV indices in a mixed PH population which was 
dominated by PAH associated with systemic sclerosis (SSc).  
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Methods 
PATIENTS 
In this prospective study 14 patients with pulmonary hypertension underwent 
baseline and short term follow-up 2DKBR of the right ventricle after intervention, 
mean follow-up was 4.8 +/- 2.6 months. 12 patients had pulmonary arterial 
hypertension (PAH) and 2 patients had chronic thromboembolic pulmonary 
hypertension (CTEPH). Table 1 shows baseline characteristics of all patients, the 
majority of the PAH patients had PAH associated with systemic sclerosis (n=8). All 
patients underwent clinical assessment including 6MWT (six minute walking test), 
NT-proBNP levels and assessment of their NYHA status at baseline and follow-up.   
After baseline 2DKBR 9 PAH patients were newly initiated on disease-targeted 
therapy (4 on single targeted therapy, 5 on double combination therapy), 3 PAH 
patients were prescribed escalation of targeted therapies (all CTD-associated PAH) 
and 2 CTEPH patients underwent pulmonary endarterectomy (PEA) during follow up 
(table 1).  
Escalation therapy was defined as change from single to double combination 
targeted therapy or from double combination to triple combination therapy including 
intravenous epoprostenol. Two CTD patients underwent additional therapy with 
intravenous cyclophosphamide during follow-up: one patient who was newly 
diagnosed with SLE-associated PAH and one patient who was escalated in targeted 
treatment for PAH associated with mixed connective tissue disease (MCTD).  
ECHOCARDIOGRAPHY 
All echocardiograms in this study were performed by the first author as part of routine 
patient assessment. Transthoracic echocardiographic images were acquired using 
standard ultrasound equipment (Philips iE33 and S5 transducer) following current 
guidelines (17, 18). For 2DKBR the VMS system was used (Ventripoint Diagnostics 
Ltd., Seattle, WA, US) as previously described (5). In brief,  a 3D RV volume is 
generated from 2DE-acquired coordinates localised in 3D space that are then 
connected by reference to a library of disease-specific RV shapes (hybrid approach). 
A magnetic localiser was attached to the S5-1 probe which detects orthogonal 
magnetic fields from a generator hanging over the patient and allows localisation at 
the point of any 2D acquisition in 3D space.  
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Seven views were obtained, six of which were standard 2D echocardiographic views, 
one view an off-axis RV apical view. After visual identification of the end-diastolic and 
end-systolic frames in four-chamber view, predefined points were plotted for each 
end-diastolic and end-systolic data sets. The coordinates of these landmarks were 
then submitted via internet to a remote server for processing by a proprietary 2DKBR 
algorithm. The algorithm interpolates between the plotted points by referencing 
against a catalogue of RV shapes generated by CMR imaging from patients with a 
known diagnosis of pulmonary hypertension (Figure 1).  
During post-processing intersections between the borders of the 3D model and the 
original 2D scan plane were checked for alignment, and in case of significant 
deviation either re-plotted or the algorithm re-run. A data set was excluded if more 
than one slice was unsuitable for analysis. A significant change in end-diastolic 
volume index (EDVI) was defined as a change of > 14%, based on results of Bland-
Altman-analysis of our previous work (twice the standard deviation of the bias)(5).  
RIGHT HEART CATHETERIZATION 
All incident patients and patients who had a change in disease targeted therapy 
underwent Right Heart Catheterization within 2 weeks of echocardiography (usually 
on the same day). The following pressures were obtained: right atrium (RA), 
pulmonary artery (PA), pulmonary capillary wedge pressure (PCWP). CO was 
determined with the Thermodilution Method. Mixed venous saturations were taken in 
Pulmonary artery and systemic oxygen saturation was obtained with finger oximetry.  
LAB TESTING 
For measurement of NT-proBNP venous blood samples were either collected at the 
end of right heart catheterization or during follow-up visits in outpatient clinic and 
processed at the Laboratory of the Royal Free Hospital.  
Statistics 
Statistical analysis was performed using SPSS 21.0 (IBM Corporation, Armonk, New 
York, USA). Kolmogorov-Smirnov tests (Lilliefors correction) were used to test for 
normal distribution of variables. Comparison of continuous variables at baseline and 
follow-up was performed by using paired t-tests or Related-Samples Wilcoxon Signed 
Rank Test in the case of non-normally distributed variables. Comparison of stable 
patients versus worsening patients was performed using unpaired t-tests or Wilcoxon 
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in the case of non-normally distributed variables. Pearson’s correlations were 
performed to calculate correlation coefficients, Spearman’s correlations were 
performed to test for correlations with non-normally distributed variables.  
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RESULTS 
Two patients had to be excluded from analysis due to insufficient quality of 
reconstruction secondary to significant patient movement, one with portopulmonary 
hypertension (POPH) and the other with SSc-associated PAH.  
With the exception of the right ventricular stroke volume index (RVSVI) and cardiac 
index (CI) there was significant improvement in all variables measured during 2DKBR 
and RHC (Table 2). Mean right ventricular end-diastolic volume index (RVEDVI) 
decreased by 18mls (p=0.015), mean right ventricular end-systolic volume index 
(RVESVI) decreased by 19 mls (p<0.001) and mean right ventricular ejection fraction 
(RVEF) increased by 9% (p=0.011). NT-proBNP levels fell by a median of 254 pmol/l 
(p=0.004) and 6 MWT results fell by a mean of 134m (p=0.005).  
Eight out of twelve patients experienced improvement of more than 14% of their 
baseline EDVI during follow up. Worsening of EDVI occurred in two patients and two 
patient remained within 14% of their EDVI at baseline (Figure 2). The patients who 
increased their EDVI were one MCTD patient who was escalated therapy from 
double to triple combination targeted therapy and one SSc-patient who was newly 
started on Sildenafil. Of seven patients with SSc-PAH (where 2DKBR data was 
available) who were initiated or escalated in therapy five patients improved their EDVI 
by more than 14%. 
In patients who improved their EDVI by more than 14% NT-proBNP levels 
consistently fell by a minimum of 73% of their baseline value (Figure 3).  
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Discussion 
In this study we documented significant short-term changes of RV-indices in patients 
who underwent an intervention for PH during follow-up, either initiation, escalation of 
targeted therapy or pulmonary endarterectomy. The majority of our patients had PAH 
associated with SSc and despite the short follow up in our study and the known 
adverse prognosis of this group of PAH patients we documented both significant 
improvement of RV volumes and RV ejection fraction.  
We have used a novel echocardiographic technique, namely knowledge-based 2D 
echocardiography reconstruction of the right ventricle to follow-up RV indices in a 
pulmonary hypertension patient population. This technique proved to be feasible in a 
busy clinical setting, all exams were done by one person using standard 2D 
echocardiography equipment plus the equipment needed for KBR. The majority of 
exams were done immediately after right heart catheterisation within the same unit or 
on the same day of their clinical follow-up.  
Our study differs from previous imaging studies in PH. It is the first to offer an insight 
into short term right ventricular changes after intervention. Despite being clinically 
severely affected with significant RV dilatation at treatment initiation they exhibited a 
reduction in RV-EDVI to a similar degree to that documented in previous 
CTEPH/PEA studies(19). Secondly our study included mostly CTD-PAH patients, 
predominantly patients with SSc associated PAH.   This group is recognised to have 
poor outcome and also might be predicted to have less favourable changes in right 
ventricular function compared with other types of PAH due to the potential additional 
burden of myocardial involvement from SSc. 
This may explain why  our results are only partly aligned with previous longitudinal 
imaging studies in PH. In CTEPH studies offering short term follow up are available 
and have demonstrated regression of RV remodelling after PEA or Balloon 
pulmonary angioplasty (19, 20). In IPAH or mixed PAH populations the situation is 
different, data is scarce on short-term follow less than 12 months after intervention. 
One 2D-echo study demonstrated improvement of RV-dimensions and parameters of 
RV-function after one year of treatment with prostacyclin analogues in a mixed PAH 
population. In this study mean 2D RV dimensions were significantly dilated at 
baseline(21). Using MRI, van Wolferen et al. conducted a study in 64 incident IPAH 
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patients and observed a significant reduction in RV-EDVI after 12 months of PAH-
targeted treatment (8). Mean EDVI in that study was mildly elevated at baseline and 
almost half of the patients received intravenous prostacyclins. Later the same group 
performed serial MRI scans in a population of 76 incident PAH patients, 
predominantly IPAH. In this second study there was no significant change in EDVI 
after 12 months, but mean EDVI was already normal at baseline (9). In that study 
31% of patients were on combination therapy and 15% on prostacyclins. The recent 
Euro-MR study involved serial CMR studies in 91 patients with PAH (mostly IPAH) 
and found significant improvements in RV ejection fraction and RV stroke volume, but 
no significant change in RV-EDVI over a period of 12 months(10). The right ventricles 
in this study were mildly enlarged, and only a minority of patients were on prostanoid 
therapy (5%) or on combination therapy (9.9%). 
 
Factors that may influence the ability to document remodelling of the RV include the 
presence of RV-dilatation at the time of the treatment initiation, the magnitude and 
effect of therapy, the chosen follow-up period or the characteristics of the pulmonary 
vascular disease itself. Our study differs from above mentioned studies that it 
included mostly SSc-patients, RV volumes were significantly dilated at baseline, 
more than half of our patients were on combination therapy and there was a 
significantly shorter period of follow-up.  
 
CTD-associated PAH differs from IPAH in its clinical course (22, 23) and also in its 
histological appearance (24). CTD-associated PAH and in particular SSC-PAH have 
a poorer RV tolerance of pulmonary hypertension than other forms of PAH (25, 26) 
which could also favour a larger change in RV indices as a response to aggressive 
therapy, at least in the short-term.  
Ventricular remodelling in PAH can be differentiated into two patterns (27): adaptive 
remodelling with concentric hypertrophy, preserved function and maladaptive 
remodelling with eccentric hypertrophy and worsening function. Our study shows that 
within several months a change from one pattern to the other can occur with medical 
therapy, even in Systemic Sclerosis.  
 
STRENGTHS OF OUR STUDY 
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This study is the first to give insight into short-term changes of RV volumes after 
intervention in a SSc-PAH dominated population. Despite the poor long-term 
prognosis of this patient group we have seen that relevant EDVI changes can occur 
within a short period of time. Also this is the first study using 2DKBR to follow-up 
patients with PAH demonstrating that this technique is feasible and easy to perform 
in daily practice.  
Our study has a number of limitations.  This was an observational single-centre study 
with relatively few subjects enrolled. Larger studies, with longer periods of follow-up 
are needed, in particular in SSc to better define RV-geometry at baseline and 
responses to therapy in this unique subpopulation within the PAH subgroup. All 
echocardiograms were done by a single person which is rarely the case in daily 
clinical practice, however there was no significant intra- and interobserver test-retest 
variability for RV-volumes in a recent validation study of 2DKBR(5). Finally, this was 
an unblinded and observational study, with the investigator aware of the patient 
treatment status both at the time of performing the echocardiogram and during 
analysis. 
CONCLUSION 
In a short-term follow-up of a SSc dominated pulmonary hypertension patient 
population we have observed significant changes in RV volumes and RV ejection 
fraction in patients after intervention, either initiation or escalation of targeted therapy 
or pulmonary endarterectomy. 2D echocardiography knowledge based reconstruction 
might be a useful alternative to other imaging modalities under various 
circumstances, e.g. regular short-term follow up or use in lower income countries.  
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Table 1 – baseline characteristics of all patients (n = 14). +/- indicates standard 
deviation (SD). NT-proBNP presented as median and interquartile range 
Age, years 
Sex, females/males 
PAH – associated with CTD/POPH 
      CTD-PAH (SSc, MCTD, Lupus) 
CTEPH, n 
Body surface area, m²  
New targeted therapy (Single/combination) 
Escalation of targeted therapy  
PEA for CTEPH 
57 +/- 12 
11/3 
10/2 
8/1/1 
2 
1.7 +/- 0.2 
4/5 
3 
2 
CTEPH (chronic thromboembolic pulmonary hypertension), CTD (connective tissue disease),  MCTD 
(mixed connective tissue disease), PAH (pulmonary arterial hypertension), PEA (pulmonary 
endarterectomy), POPH (portopulmonary Hypertension), RVEDVI (right ventricular end-diastolic 
volume index), RVEF (right ventricular ejection fraction), RVESVI (right ventricular end-systolic 
volume index), RVSVI (stroke volume index), SSc (Systemic Sclerosis),  
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Table 2 – baseline and follow up variables  
 Pre Post p-value 
NYHA FC 
NT-pro BNP (pmol/l) 
6MWT (m) 
PVR, (dyn)   
CI (RHC) (l/min) 
PAm (mmHg)  
RVEDVI (ml/m²) 
RVESVI (ml/m²) 
RVSVI (ml/m²) 
RVEF (%) 
3.2 +/- 0.4 
200; 364 
241 +/- 124 
720 +/- 280 
2.8 +/- 0.7 
50 +/- 7 
107 +/- 22 
74 +/- 20 
32 +/- 12 
30 +/- 9 
2.1 +/- 0.5 
83; 87 
375 +/- 118 
435 +/- 159 
3.2 +/- 0.6 
38 +/- 9 
89 +/- 20  
55 +/- 17  
 34 +/- 12 
 39 +/- 9 
0.004# 
0.004# 
0.005 
0.002 
0.25 
<0.001 
0.015 
 <0.001 
0.6 
0.011 
# Related-Samples Wilcoxon Signed Rank Test. NT-pro BNP given as median and interquartile range. 
6MWT (six minute walking test), CI (cardiac index), RHC (right heart catheterization), Pam (mean 
pulmonary artery pressure), PVR (pulmonary vascular resistance) 
 
  
13 
 
Figure captions 
Figure 1 – 3D model of both baseline and follow-up knowledge-based reconstruction 
of the right ventricle in a patient with newly diagnosed PAH associated with Systemic 
Sclerosis (female, 50 years). Patient was prescribed combination therapy (Tadalafil, 
Bosentan). (RVEDVI at baseline 123.5mls, RVEDVI at follow up 105.8mls. RVEF at 
baseline 22%, at follow up 42%) 
 
 
Figure 2 – EDVI at baseline and follow up of all patients. Continuous line:  
improvement of more than 14% of baseline EDVI. Dotted line: patients within 14% of 
baseline EDVI (stable). Dashed line: worsening of more than 14% of baseline EDVI  
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Figure 3 – NT-proBNP trend in all patients with EDVI improvement of more than 14% 
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